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Background: Metformin, which is widely used as an antidiabetic agent, has recently been reported to reduce
cancer risk and improve prognosis in certain malignancies. However, the specific mechanisms underlying the effect
of metformin on the development and progression of several cancers including oral squamous cell carcinoma
(OSCC) remain unclear. In the present study, we investigated the effects of metformin on OSCC cells in vitro and
in vivo.
Methods: OSCC cells treated with or without metformin were counted using a hemocytometer. The clonogenic
ability of OSCC cells after metformin treatment was determined by colony formation assay. Cell cycle progression
and apoptosis were assessed by flow cytometry, and the activation of related signaling pathways was examined by
immunoblotting. The in vivo anti-tumor effect of metformin was examined using a xenograft mouse model.
Immunohistochemistry and TUNEL staining were used to determine the expression of cyclin D1 and the presence
of apoptotic cells in tumors from mice treated with or without metformin.
Results: Metformin inhibited proliferation in the OSCC cell lines CAL27, WSU-HN6 and SCC25 in a time- and
dose-dependent manner, and significantly reduced the colony formation of OSCC cells in vitro. Metformin induced
an apparent cell cycle arrest at the G0/G1 phase, which was accompanied by an obvious activation of the AMP
kinase pathway and a strongly decreased activation of mammalian target of rapamycin and S6 kinase. Metformin
treatment led to a remarkable decrease of cyclin D1, cyclin-dependent kinase (CDK) 4 and CDK6 protein levels and
phosphorylation of retinoblastoma protein, but did not affect p21 or p27 protein expression in OSCC cells. In
addition, metformin induced apoptosis in OSCC cells, significantly down-regulating the anti-apoptotic proteins Bcl-2
and Bcl-xL and up-regulating the pro-apoptotic protein Bax. Metformin also markedly reduced the expression of
cyclin D1 and increased the numbers of apoptotic cells in vivo, thus inhibiting the growth of OSCC xenografts.
Conclusions: Our data suggested that metformin could be a potential candidate for the development of new
treatment strategies for human OSCC.
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Oral squamous cell carcinoma (OSCC), which is the
most common cancer of the oral cavity, is one of the
leading causes of cancer-related death [1,2]. Currently,
therapeutic strategies for OSCC include surgery, radi-
ation and chemotherapy. However, despite advances in
multimodal treatments, the overall survival rate of
OSCC has not been improved significantly in the last
several decades [2]. In addition, functional or cosmetic
deficiencies and severe complications are often asso-
ciated with the disease even after the treatment. There-
fore, the identification of novel and effective therapeutic
agents to inhibit cancer cell growth in OSCC is essential.
Metformin (1, 1-dimethylbiguanide hydrochloride) is
an antihyperglycemic drug commonly used in the treat-
ment of type 2 diabetes. Its anti-diabetic effect is
mediated by the activation of AMP-activated protein
kinase (AMPK), which inhibits hepatic gluconeogenesis
and enhances glucose uptake in skeletal muscle [3]. In
addition to its anti-diabetic properties, numerous studies
have shown that metformin possesses anticancer activity,
which has attracted increasing attention. In basic investi-
gations, metformin inhibited cell proliferation in several
human malignancies including gastric cancer [4], pan-
creatic cancer [5], medullary thyroid cancer [6], breast
cancer [7] and endometrial carcinoma [8]. Metformin
also suppressed tumor growth in xenograft mouse mod-
els of melanoma [9], ovarian cancer [10], prostate cancer
[11] and breast cancer [12]. Furthermore, in a cancer
animal model, metformin prevented tobacco carcinogen-
induced lung tumorigenesis [13] and decreased the inci-
dence and size of mammary adenocarcinomas in Her2/
c-Neu transgenic mice [14]. Results from epidemiologic
surveys confirm that metformin has significant effects
on tumorigenesis. The use of metformin in diabetic
patients was associated with significantly lower risks of
cancer incidence and mortality [15]. Colorectal cancer
patients with diabetes treated with metformin as part of
their diabetic therapy appeared to have a superior overall
survival rate [16]. However, the mechanisms underlying
the suppression of cancer growth by metformin are
complex, and remain relatively unknown.
Here, we demonstrated that metformin inhibited the
growth of OSCC cells by blocking cell cycle progression
at the G0/G1 phase and inducing apoptosis. Further-
more, metformin treatment was associated with the acti-
vation of the AMP kinase pathway and the suppression
of mammalian target of rapamycin (mTOR) and S6 kin-
ase (S6K) activation. Metformin treatment also led to
a significant decrease of cyclin D1 protein level and
retinoblastoma protein (pRb) phosphorylation. Cyclin-
dependent kinase (CDK) 4 and CDK6 were also decreased
by metformim. Moreover, a significant down-regulation
of the anti-apoptotic proteins Bcl-2 and Bcl-xL and up-regulation of the pro-apoptotic protein Bax were observed
in OSCC cells following metformin treatment. A colony
formation assay revealed that metformin reduced the
clonogenic ability of OSCC cells in vitro. More importantly,
metformin markedly decreased the expression of cyclin D1
and increased the number of apoptotic cells in a xeno-
graft model, showing the suppression of OSCC tumor
growth in vivo.Methods
Animals
BALB/c nude mice (male, 4 weeks of age) were pur-
chased from Shanghai Laboratory Animal Center
(Shanghai, China) and maintained in the animal care
facilities of the Ninth People’s Hospital, Shanghai Jiao
Tong University School of Medicine under pathogen-free
conditions. Animal welfare and experimental procedures
were carried out strictly in accordance with the Guide for
the Care and Use of Laboratory Animals (The Ministry of
Science and Technology of China, 2006) and the related
ethical regulations of the hospital. All efforts were made
to minimize animal suffering and to reduce the number
of animals used. All experimental procedures received
approval by the Laboratory Animal Care and Use Com-
mittees of the hospital.Cell lines and reagents
Three human OSCC cell lines (CAL27, WSU-HN6 and
SCC25) were included in this study. CAL27 and SCC25
were from the American Type Culture Collection
(ATCC), and WSU-HN6 was from the National Insti-
tutes of Health (NIH). All OSCC cells were provided by
the Shanghai Key Laboratory of Stomatology, the Ninth’s
Hospital, Shanghai Jiao Tong University School of Medi-
cine. Metformin (1,1-dimethylbiguanide hydrochloride)
was purchased from Sigma Chemical (St. Louis, MI,
USA). Antibodies used for western blot analyses were
from the following sources: antibodies against AMPKα,
phospho-AMPKα (Thr172) (p-AMPKα), p21 and p27
were obtained from Cell Signaling Technology (Denvers,
MA, USA); antibodies against Bax, Bcl-2 and Bcl-xL were
obtained from BD Pharmingen (San Diego, CA, USA);
anti-phospho-mTOR (Ser2448) (p-mTOR), phospho-
pRb (Thr821) (p-pRb), cyclin D1, CDK4, CDK6 and
phospho-S6K (p-S6K) antibodies were from Eptitomics
(Burlingame, CA, USA). Anti-β-actin (clone AC-40) was
purchased from Sigma. IRDye 800CW goat anti-mouse
secondary antibody and goat anti-rabbit secondary
antibody were obtained from LI-COR Biotechnology
(Lincoln, NE, USA). PI/Rase staining buffer and the
FITC Annexin V apoptosis detection kit were purchased
from BD Pharmingen.
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CAL27 and WSU-HN6 were cultured in Dulbecco’s
modified Eagle medium (DMEM) (Invitrogen, Carlsbad,
CA, USA) supplemented with penicillin (100 units/ml),
streptomycin (100 μg/ml) and 10% (v/v) heat-inactivated
fetal bovine serum (FBS) (Invitrogen). SCC25 was cul-
tured in F12/DMEM (Invitrogen) supplemented with
the same concentrations of FBS and penicillin and
streptomycin. Cells were incubated at 37°C in a humidified
atmosphere containing 5% CO2.
Cell proliferation assay
Human OSCC cells (5 × 104 cells/well) were plated into
12-well plates. After 24 hours (h), cells were treated with
metformin at the indicated concentrations or the same
volume of culture medium. After incubation with met-
formin for 24, 48 or 72 h, cells were extensively rinsed
in Dulbecco’s phosphate buffered saline (PBS) to remove
any loosely attached or floating cells. The cells were then
harvested by trypsinization and the cell number was
determined using a hemocytometer.
Cell clonogenic assay
Cells were seeded into 6-well plates in triplicates at a
density of 1000 cells/well in 2 ml of medium containing
10% FBS. After 24 h, cultures were replaced with fresh
culture medium containing the indicated concentrations
of metformin in a 37°C humidified atmosphere with 95%
air and 5% CO2, and grown for 3 weeks. The culture
medium was changed once every 3 days. The cell clones
were stained for 15 min with a solution containing 0.5%
crystal violet and 25% methanol, followed by three rinses
with tap water to remove excess dye. Colonies consisting
of >50 cells were counted under a microscopy.
Cell cycle and apoptosis analysis
Tumor cells (2 × 105 cells/well) were seeded in 6-well
plates. After 24 h, the medium was removed and
replaced by fresh culture medium containing 0 mmol/L
(mM) or 20 mM metformin for different time. The cell
cycle was analyzed by measuring the amount of propi-
dium iodide (PI)-labeled DNA in ethanol-fixed cells. In
brief, cells were treated for 24 h, harvested by trypsiniza-
tion and fixed with cold 70% ethanol. Cells were then
stained for total DNA content with PI/Rase staining buf-
fer according to the manufacturer’s instructions. Cell
cycle distribution was analyzed using a flow cytometer
(Becton Dickinson, San Jose, CA, USA) and ModFit soft-
ware. Apoptotic and necrotic cell death were analyzed
by double staining with FITC-conjugated Annexin V and
PI, which is based on the binding of Annexin V to apop-
totic cells with exposed phosphatidylserine and PI label-
ing of late apoptotic/necrotic cells with membrane
damage. Tumor cells were treated for 24 and 48 h.Staining was performed according to the manufacturer’s
instructions. Apoptosis was analyzed by flow cytometry,
and data were processed with the FlowJo software.
Western blot analysis
Tumor cells were seeded in a 6-well plate at a density of
5 × 105 cells per well. After 24 h, the medium was
replaced with fresh culture medium containing 0 mM or
20 mM metformin for different times. Cells were collected
and lysed in RIPA buffer (150 mM NaCl, 10 mM Tris–
HCl, pH 8.0, 1% Nonidet P-40 (NP-40), 0.5% deoxycholic
acid, 0.1% SDS, 5 mM EDTA) containing 0.7% phenyl-
methylsulfonyl fluoride (PMSF), 0.2% aprotinin, 0.2% leu-
peptin, and sodium metavanadate. Samples (50 μg
protein) were incubated at 100°C for 5 min, separated on
10% (w/v) SDS-PAGE gels, and electrophoretically trans-
ferred to a PVDF membrane (Bio-Rad, Hercules, CA,
USA). Nonspecific sites were blocked with a solution
containing 5% non-fat milk powder in TBS/Tween20
(TBS/T) for 2 h at room temperature. The membrane
was probed with antibodies against β-actin, AMPKα,
pAMPKα, P21, P27, Bax, Bcl-2, Bcl-xL, pmTOR, pRb,
cyclin D1, CDK4, CDK6 and pS6K in TBS/T contain-
ing 5% bovine serum albumin (BSA) overnight at 4°C,
and then incubated with IRDye 800CW goat anti-
mouse secondary antibody or goat anti-rabbit secondary
antibody at a dilution of 1:10000. Antibody-antigen com-
plexes were detected using the OdysseyW Infrared Imaging
system (LI-COR Biosciences, Lincoln, NE, USA).
In vivo anti-tumor activity
For xenograft implantation, a total of 2 × 106 CAL27
cells/mouse were injected subcutaneously into the back
next to the right hind limb, and permitted to grow until
palpable. Then mice were randomly assigned into con-
trol and treated groups and treatment was initiated. The
metformin treated group received oral administration of
metformin in drinking water (200 μg/ml) for 15 days,
whereas the control group received drinking water only.
Tumors were measured every 3 days with vernier cali-
pers and tumor volumes were calculated according to
the following formula: tumor volume (mm3) = a × b2 ×
0.52, where a is the longest diameter and b is the shortest
diameter. Body weight of the mice was also recorded. At
the end of the experiments, tumor-bearing mice were
sacrificed, and tumors were weighed after being separated
from the surrounding muscles and dermis. Finally, the
tumors were fixed with 4% phosphate-buffered parafor-
maldehyde and embedded in paraffin.
TUNEL (terminal deoxynucleotidyl transferase
(TdT)-mediated nick end labeling) staining
Paraffin-embedded tumor samples were assayed for
DNA fragmentation using a TUNEL assay with the In
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chemicals, Indianapolis, IN, USA). In brief, 5-μm-thick
paraffin sections of the tumor were deparaffinized in
xylene and rehydrated in decreasing concentrations of
ethanol. Sections were rinsed in distilled water and incu-
bated in 3% hydrogen peroxide in methanol for 5 min to
block endogenous peroxidase activity. Tissue sections
were then incubated in 20 μg/ml proteinase K (DAKO
Corporation, Carpinteria, CA, USA) for 15 min, washed
with PBS, incubated in equilibration buffer and then in
TdT enzyme solution in a humidified chamber at 37°C for
60 min. The sections were subsequently rinsed in PBS,
and then incubated with streptavidin-peroxidase conju-
gate for 30 min. Peroxidase activity was detected by appli-
cation of DAB (Vector Laboratories, Burlingame, CA,
USA). Apoptotic cells were identified by a dark brown nu-
clear stain observed under a light microscope. A total of
10 tissue sections were analyzed for each animal.
Immunohistochemical (IHC) staining
Cyclin D1 expression in xenograft tumor samples was
determined by IHC staining. Briefly, 5-μm thick
paraffin-embedded tumor sections were deparaffinized
in xylene and rehydrated in decreasing concentrations of
ethanol. Sections were subjected to heat-induced antigen-
retrieval in citric acid buffer (pH 7.0) for 20 min, blocked
in 5% normal goat serum for 30 min, and incubated in 3%
hydrogen peroxide to suppress endogenous peroxidase ac-
tivity. Sections were then treated with an anti-cyclin D1
(Epitomics) antibody at a dilution of 1:150 at 4°C over-
night, followed by peroxidase-conjugated goat anti-rabbit
antibody for 1 h at room temperature. Finally, sections
were developed in a substrate solution of DAB (Vector
Laboratories) and counter-stained with hematoxylin. All
sections were examined under light microscopy.
Statistical analysis
Each experiment or assay was performed at least three
times, and representative examples are shown. Data were
reported as means ± SD. The statistical significance of
the differences was analyzed by Student’s t-test. The
value of p < 0.05 was considered significant.
Results
Metformin inhibits the proliferation of OSCC cells and
reduces colony formation in vitro
To evaluate the growth inhibitory effect of metformin
on human OSCC cells in vitro, three OSCC cell lines
were included in our study: CAL27, WSU-HN6 and
SCC25. Cells were seeded in 12-well plates and treated
with or without 5, 10 and 20 mmol/L (mM) metformin
for different time. Cell numbers were then determined
by a hemocytometer. As shown in Figure 1A, metformin
significantly inhibited proliferation in all three OSCCcell lines in a time- and dose-dependent manner. The
ability of these three cell lines to form colonies on 6-well
cell culture plates in the presence or absence of metfor-
min was examined for a period of 3 weeks. Metformin
significantly reduced colony formation at concentrations
as low as 5 mM (Figure 1B). The inhibitory effect of met-
formin on colony formation was also dose-dependent, as
shown in Figure 1B. At the highest concentration of
20 mM metformin, colony formation was reduced over
90% as compared to the untreated controls (0 mM).
Taken together, these results indicate that metformin
inhibits the growth of OSCC cells.
Metformin induces OSCC cell cycle arrest
The possible effect of metformin on cell cycle progression
in OSCC cells was examined by flow cytometry. Treat-
ment of proliferating CAL27, WSU-HN6 and SCC25 cells
with 20 mM metformin for 24 h caused delayed entry
into S phase and induced G0/G1 arrest. Metformin treat-
ment increased the proportion of cells in the G0/G1
phase in all three OSCC cell lines compared to control
cells (69.7% vs. 50.86% in CAL27, 77.96% vs. 56.54% in
WSU-HN6, and 64.03% vs. 43.51% in SCC25) (Figure 2A).
The proportion of OSCC cells in the S phase decreased
accordingly, whereas there was no significant change in
the number of cells in the G2/M phase.
The expression of various cell-cycle-related molecules
in OSCC cells treated with or without 20 mM metfor-
min for 24 h was then examined by western blot. The
most remarkable change was the loss of cyclin D1, a key
protein implicated in the transition from the G0/G1 to
the S phase (Figure 2B). Increased levels of p-AMPKα in
metformin-treated cells indicated the activation of the
AMPK pathway. The protein levels of p-mTOR, p-S6K
and p-pRb also decreased dramatically in response to
metformin treatment (Figure 2B). Analysis of the expres-
sion of other cell-cycle-related proteins involved in the
G0/G1 transition revealed an obvious decrease of CDK4
and CDK6 levels in OSCC cells treated with metformin.
However, no significant changes were detected in the
expressions of p21 and p27. These results clearly dem-
onstrate that metformin affects the expression and the
phosphorylation of key cell cycle regulatory proteins
leading to G0/G1 arrest in human OSCC cells.
Metformin induces apoptosis of OSCC cells
To determine whether metformin induced apoptosis,
OSCC cells were treated with or without 20 mM metfor-
min for 24 h and 48 h and analyzed by flow cytometry.
The results showed that metformin induced a dramatic
increase in the proportion of apoptotic tumor cells 48 h
after treatment in CAL27, WSU-HN6 and SCC25 cells
(25.4%, 24.4% and 43.7%, respectively), with 11.4%, 8.4%
and 15.5% of apoptotic cells at 24 h after treatment,
Figure 1 Metformin inhibits OSCC cell proliferation and colony formation. (A) 5 × 104 cells/well human OSCC cells (CAL27, WSU-HN6, and
SCC25) were plated onto 12-well plates and incubated at 37°C with 5% CO2. After 24 h, the culture medium was replaced with fresh culture
medium containing 0 mM, 5 mM, 10 mM or 20 mM metformin for different time. Cell numbers were determined using a hemocytometer at each
indicated time point. (B) Human OSCC cells (CAL27, WSU-HN6, and SCC25) were grown in 6-well plates (1000 cells/well). After 24 h, the culture
medium was replaced with fresh culture medium containing 0 mM, 5 mM, 10 mM or 20 mM metformin every 3 days for 3 weeks. Cell colonies
were stained and counted as described in the Methods section. Data are representative of three independent experiments.
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tumor cells in the control groups of CAL27, WSU-HN6
and SCC25 were 7.8%, 5.5% and 9.2%, respectively
(Figure 3A). To investigate the mechanisms underlying
the apoptosis-inducing effect of metformin in OSCC
cells, the levels of apoptosis-related proteins such as Bcl-
2, Bcl-xL and Bax were measured in total protein from
tumor cells treated with or without 20 mM metformin
for 24 h and 48 h by western blot. Metformin signifi-
cantly down-regulated the expression of the anti-
apoptotic proteins Bcl-2 and Bcl-xL and up-regulated
the pro-apoptotic protein Bax (Figure 3B). These results
indicate that an apoptotic mechanism is implicated in
the metformin-induced inhibition of proliferation in
OSCC cells.
Metformin impairs OSCC growth in vivo
Finally, we investigated whether metformin could pre-
vent OSCC progression in vivo. The CAL27 cell line was
randomly selected for the establishment of the OSCC
xenograft nude mouse model. After solid tumors were
palpable (day 8), mice were randomly assigned intocontrol and treated groups. Metformin was administered
orally to the treated group in drinking water (200 μg/ml),
whereas the control mice only received fresh drinking
water. During our experiments, no obvious side effects
were observed in mice treated with metformin (data not
shown). Tumor volumes and tumor weights were mea-
sured. Consistent with our in vitro results, oral adminis-
tration of metformin led to a substantial inhibition of
tumor growth by 58.77% (Figure 4A). CAL27 xenograft
nude mice treated with metformin had a significantly
reduced tumor burden compared with control mice, as
reflected in the obvious reduction in the sizes and
weights of tumors from metformin-treated mice
(Figure 4B and 4C). The mean weights of the excised
tumors were approximately 69.3% lower in mice treated
with metformin than in untreated mice. To determine
whether metformin affected cyclin D1 protein levels and
apoptosis of tumor cells in vivo, we further analyzed
cyclin D1 expression and apoptotic tumor cells in xeno-
graft tumors by IHC and TUNEL staining, respectively.
Metformin markedly reduced the expression of cyclin D1
and increased the number of apoptotic tumor cells
Figure 2 Metformin blocks cell cycle progression at the G0/G1 phase. Human OSCC cells (CAL27, WSU-HN6, and SCC25) were grown in 6-
well plates (2 × 105 cells/well). After 24 h, the culture medium was removed and replaced with fresh culture medium containing 0 mM or 20 mM
metformin for an additional 24 h. (A) Cell cycle progression in OSCC cells was assessed by flow cytometry. (B) The expression of related cell-cycle
regulatory proteins in arrested and proliferating OSCC cells treated with or without metformin was assessed by immunoblotting. One
representative experiment out of three is shown.
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similar to the in vitro results, metformin impairs the
growth of OSCC cells in vivo through the induction of
cell cycle arrest and apoptosis.
Discussion
As a stable, inexpensive and highly effective oral drug,
metformin has been used for the treatment of type 2
diabetes for several decades. It stimulates glucose uptake
and increases fatty acid oxidation in muscle and liver
with no adverse effects [3,17]. Recent data indicate that
metformin can protect from cancer and inhibit the pro-
liferation of several types of cancer cells in vitro and
in vivo, such as breast cancer [18], gastric cancer [4],
pancreatic cancer [19], and thyroid cancer [6]. The anti-
tumor effects of metformin have been investigated in
different types of adenocarcinoma; however, its effects
on squamous cell carcinoma, a malignant tumor ofepidermal keratinocytes that invades the dermis, have
not yet been well defined. Adenocarcinoma and squa-
mous cell carcinoma can differ significantly in their
symptoms, natural history, prognosis, and response to
treatment owing to differences in cellular origin. In the
present study we focused on the effects of metformin on
OSCC, a common squamous cell carcinoma of the head
and neck. The present findings are significant because 1)
we demonstrate for the first time that metformin exerts
potent anti-OSCC effects both in vitro and in vivo; 2)
metformin induces cell cycle arrest at the G0/G1 phase
and apoptosis of OSCC cells associated with the modu-
lation of cell cycle-regulatory and apoptosis-related
protein expression. CDK inhibitors such as p21 and
p27 have been shown to play an important role in the
inhibitory effects of metformin in previous studies
[18,20]. However, in the present study, we did not observe
significant changes of these proteins in OSCC cells
Figure 3 Metformin induces apoptosis of OSCC cells. Human OSCC cells (CAL27, WSU-HN6, and SCC25) were grown in 6-well plates (2 × 105
cells/well). After 24 h, the culture medium was removed and replaced with fresh culture medium containing 0 mM or 20 mM metformin for
another 24 h or 48 h. (A) Apoptosis of OSCC cells was analyzed by flow cytometry. (B) The expression of the anti-apoptotic proteins Bcl-2 and
Bcl-xL and the pro-apoptotic protein Bax in OSCC cells treated with or without metformin was assessed by western blot. Data is representative of
three independent experiments.
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be due to the differences in the properties of the different
types of cancer cells.
A previous study showed that specific cyclin/CDK
complexes are activated at different intervals during
the cell cycle and complexes of CDK4 and CDK6 with
cyclin D1 are required for G1 phase progression [21].
Down-regulation of cyclin D1 in response to metfor-
min has been shown in several cancer cell linesincluding breast cancer [18] and prostate cancer [11]
cells. The effects of metformin on the catalytic subu-
nits of cyclin D1, CDK4 and CDK6 in OSCC cells,
however, remain unknown. In the present study, met-
formin blocked cell cycle progression at the G0/G1
phase, which was correlated with a remarkable decrease
in the expression of cyclin D1 and phosphorylation of
pRb, two major cell-cycle regulators. Cyclin D1 binds to
and activates CD4/CDK6, which then phosphorylates
Figure 4 In vivo anti-tumor effects of metformin in OSCC xenografts in nude mice. A total of 2 × 106 CAL27 cells/mouse were injected
subcutaneously into the back next to the right hind limb, and permitted to grow until palpable. Metformin was administered orally for 15 days;
control mice received drinking water only. (A) Graphs represent the average tumor volumes of CAL27 xenografts in mice from the control and
metformin–treated groups. (B) Representative images of tumors from mice in the two groups. (C) Weight of tumors from the control and
metformin-treated groups. (D) Cyclin D1 expression and apoptotic tumor cells in tumors from mice treated with or without metformin were
assessed by IHC and TUNEL staining, respectively (original magnification is 200×). Five mice were included for each group, and results are
representative of three experiments. (***p < 0.001).
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tion factor E2F, which activates the transcription of genes
required for G1/S phase transition [22]. Cyclin D1 gene
amplification and overexpression are observed in several
types of human cancer including OSCC [23-25]. Further-
more, overexpressed cyclin D1 is associated with
enhanced tumor growth and chemotherapy resistance
[24,26]. Thus, cyclin D1 is a potential molecular target for
the treatment of OSCC. In addition to its effect on cyclin
D1, metformin strongly inhibits the phosphorylation of
pRb in OSCC cells, blocking the activation of E2F. Activa-
tion of E2F by disruption of the Rb tumor suppressor path-
way is a key event in the development of many human
cancers. Increased expression of E2F is associated with ma-
lignant transformation in OSCC, and down-regulation of
this transcription factor is associated with induction of
apoptosis and cell cycle arrest in OSCC cells [27,28].
Therefore, our results suggest that metformin could bedeveloped as a potential therapeutic agent to block the
progression of OSCC.
In the present study, metformin activated the AMPK
pathway and inhibited S6K and mTOR phosphorylation
in OSCC cells, suggesting that the mTOR pathway may
be involved in mediating the effect of metformin in these
cells. However, the role of AMPK in the activation of
mTOR signaling is the subject of controversy. Using
siRNA against the two catalytic subunits of AMPK, Ben
Sahra et al. demonstrated that the anti-proliferative effect
of metformin was mediated by the mTOR pathway inde-
pendently of AMPK [11]. On the other hand, Zakikhani
et al. showed that metformin inhibited cell growth via
the α1 AMPK subunit in MCF-7 breast cancer cells [29].
Although our results clearly showed the growth inhibi-
tory effect of metformin in OSCC, the involvement of
the AMPK pathway in the anti-tumor effect of metformin
on OSCC remains to be elucidated. Moreover, because
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metabolism, it would be interesting to determine whether
the metabolic consequences of metformin are related to
its anti-proliferative effects.
In addition to the effect of metformin on the cell cycle,
we examined whether the anti-neoplastic effect of this
agent is mediated by the induction of apoptosis. Our flow
cytometry results demonstrated that metformin signifi-
cantly induced apoptosis in all three OSCC cells lines.
These findings were further confirmed by our western
blot results showing a significant down-regulation of the
anti-apoptotic proteins Bcl-2 and Bcl-xL and the up-
regulation of the pro-apoptotic protein Bax. Several death
and survival genes, such as Bcl-2 or Bax, which are regu-
lated by extracellular factors, are involved in apoptosis
[30]. When the ratio of pro-apoptotic Bcl-2 family mem-
bers (Bax, Bad) to anti-apoptotic Bcl-2 family members
(Bcl-2, Bcl-xL and Mcl-1) increases, pores form in the
outer mitochondrial membrane, liberating apoptogenic
mitochondrial proteins to activate caspases and induce
apoptosis [31]. Data concerning the effect of metformin
on apoptosis in cancer cells are limited and controversial.
A recent study indicated that metformin suppressed the
growth of human head and neck squamous cell carcin-
oma mainly via G1 arrest, which coincided with a de-
crease in the protein levels of CDKs, cyclins and CDK
inhibitors [32]. Ben Sahra et al. also showed that metfor-
min blocked the cell cycle in the G0/G1 phase in prostate
cancer cells and did not induce apoptosis [11]. In con-
trast, metformin has been shown to promote apoptosis in
pancreatic cancer [19] and melanoma [9] cells. This dis-
crepancy between studies regarding the effect of metfor-
min on apoptosis may be the result of variations in
experimental conditions, cell-specific functions and/or
different cell origin, and suggests that further investiga-
tion is necessary. Moreover, Hirsch et al. [33] reported
that low doses of metformin could inhibit cellular trans-
formation and selectively kill cancer stem cells in four
genetically different types of breast cancer, thus inhibited
the tumor growth both in vitro and in vivo. Whether
similar mechanisms also contribute to the anti-cancer
effect of metformin in OSCC still needs to be identified
in our further study.
Although the doses of 20 mM metformin used in our
in vitro study are similar to those used in prior studies
on gastric cancer [4], melanoma [9] and breast cancer
[29], one can still argue that these doses are above
physiological levels. Indeed, the concentration of metfor-
min in the blood of type 2 diabetic patients treated with
the drug is approximately 30 ~ 60 μmol/L [34], which
indicates that the doses used in our study exceeded the
therapeutic level by 300-fold. However, it has been
reported that metformin accumulates in tissues at concen-
trations similar to the dose used in our experiments[35,36]. Moreover, tumor cells in culture are grown under
high concentrations of glucose and 10% FBS, which results
in excessive growth stimulation. This may also contribute
to the high dose of metformin required to exert anti-
tumor effects in a cell culture system compared to the
dose used in patients with diabetes. Furthermore, accord-
ing to the study of Ben Sahra et al., the doses of 1 to
3 mg/day metformin caused no side effect in mice, which
was equal to the dosage used for patients [11], we
obtained a strong inhibition of OSCC tumor growth
in vivo. 200 μg/ml metformin administered orally signifi-
cantly decreased OSCC growth in a xenograft model. This
result is of particular importance as it is the first time that
metformin is shown to inhibit OSCC tumor growth
in vivo.Conclusions
The present study used a cell culture system and a
tumor xenograft mouse model to demonstrate for the
first time that metformin effectively inhibits OSCC
cell proliferation and tumor growth in vitro and
in vivo. Our results suggest that metformin could be
a potential candidate for the development of novel
treatment strategies for human OSCC, which warrants
further investigation.
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